(주)지아이셀

Collection of whole blood from patient (for autologous) or healthy donor (for allogenic)
Isolation of immune cell from the blood using semi-automated and fully closed cell isolation process
Activation of isolated immune cells are with ancillary protein class I developed by GI Cell, Inc.
Expansion of the immune cells with ancillary protein class II developed by GI Cell, Inc.
Infusion of the processed specific-immune cells into the patient's bloodstream to treat a disease

Key features of T.O.P. NK^® Cell

Tumor-targeting Optimally Primed (T.O.P.) NK Cell.
T.O.P. NK cells are robustly activated and amplified using ONLY the ancillary proteins in the Nkpure expander platform.
T.O.P. NK cells are highly pure (>99%) and safe to use as NO feeder cells are used during the cultivation process.
Even with NO genetic modification or viral transduction, CD16 (FcγRIII) expression and cytotoxic granule contents are HIGHLY ELEVATED in T.O.P NK cells.
High CD16 expression enables T.O.P NK cells to target and kill tumor cells via antibody-dependent cell cytotoxicity (ADCC).
Robust cytotoxic granule contents elevate T.O.P. NK cells’ killing competency.

Key features of Nano NK^® Cell

Nanoparticle-armed (Nano) NK Cells are NK cells carrying pH-sensitive nanoparticles loaded with a chemotherapeutic drug.
Tumor-specific homing and targeting by the NK cells grants major advantages over conventional chemotherapy, which causes systemic adverse effect to the recipients.
Nano NK cells carry out tumor-targeted drug delivery, which significantly reduce the toxicity of released chemotherapeutic agent.
Upon engaging a tumor cell, Nano NK cell releases its cytotoxic granules, causing the immunological synapse between engaging NK cell and target tumor cell to turn acidic.
Acidification of the surroundings prompts nanoparticle disassembly and release of chemotherapeutic drug directly onto the tumor cell, resulting in tumor cell killing.
This technology could also be adapted to reinforce cytotoxic T lymphocytes with chemo-loaded nanoparticles.

Key features of X-Pres T Cell^®

Personalized, tumor-targeting autologous cytotoxic T lymphocytes for cancer treatment.
Personalized tumor antigen profiling is performed to identify target antigens.
Matching target antigens are selected from the GI Cell’s “in-house engineered” tumor antigen library.
Through a process called “cross-presentation,” CTLs are selectively educated to eliminate cancer cells expressing the target antigens.
Educated tumor-specific CTLs (X-Pres T cells) are further amplified and activated using GI Cell’s ancillary proteins.
The cultivation process with GI Cell’s ancillary proteins increases purity of X-Pres T cells, eliminating the need for further (and expensive) cell purification steps.
X-Pres T cells are administered to the patient as treatment for cancer.

Key features of Drone Treg^® Cell

Regulatory T cells play important role in maintaining tolerance and immune cell homeostasis.
Tregs are crucial in controlling chronic inflammatory diseases as they can suppress inflammatory immune responses through secretion of inhibitory cytokines.
Target organ-specific regulatory T cell therapy platform which induces controlled expression of organ-specific homing receptors from the Foxp3hi regulatory T cell isolated from patient’s blood.
Drone Treg Cells expressing gut-specific homing markers, CCR9 and α4β7 integrin, induce migration to lesion of patient’s gut after infusion.
In intestinal autoimmune diseases, APCs and effector T cells elicit and propagate aberrant inflammatory responses towards innocuous antigens, such as food particles or commensal microbiomes, which leads to tissues damage in the gut.
Drone Treg Cells in the gut can effectively control the inflammatory APCs and effector T cells by releasing anti-inflammatory cytokines and induce repair of damaged tissues.

R&D